Drugs /

hydroxyurea

Back to Drugs List

Overview

Generic Name(s):
hydroxyurea
Trade Name(s):
Droxia and Hydrea
NCI Definition [1]:
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)

Clinical Trials

View Clinical Trials for hydroxyurea

Hydroxyurea has been investigated in 7 clinical trials, of which 5 are open and 2 are closed. Of the trials investigating hydroxyurea, 4 are phase 2 (3 open) and 3 are phase 3 (2 open).

CDKN2A Overexpression, HPV Negative, and HPV Positive are the most frequent biomarker inclusion criteria for hydroxyurea clinical trials.

Head and neck squamous cell carcinoma, essential thrombocythemia, and myelodysplastic syndromes are the most common diseases being investigated in hydroxyurea clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Hydroxyurea
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Hydroxyurea
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating hydroxyurea and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Droxia, Hydrea, hyd, sq 1089, hydroxycarbamide, hu, hydroxyurea, n-hydroxyurea, hydroxyharnstoff, hidroxicarbamida, hydroxyurea (substance), hydroxycarbamidum, hydurea, hydroxycarbamid, sq-1089, oxyurea, litalir, 937, n-carbamoylhydroxylamine, oncocarbide, carbamohydroximic acid, urea, hydroxy-, carbamoyl oxime, onco-carbide, hydroxyurea, 38558, 9235, 7179, hydroxyurea [chemical/ingredient], carbamohydroxamic acid, 32065, wr 83799, hydroxyurea (product), onco-carbide, carbamyl hydroxamate, oxeron, 127-07-1, syrea
Drug Categories [2]:
Antimetabolites
NCIT ID [1]:
C560
SNOMED ID [1]:
C-78100

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.